Literature DB >> 25735335

RASAL1 attenuates gastric carcinogenesis in nude mice by blocking RAS/ERK signaling.

Hong Chen1, Ji-Yi Zhao, Xu-Chen Qian, Zheng-Yuan Cheng, Yang Liu, Zhi Wang.   

Abstract

Recent studies have suggested that the RAS protein activator like-1 (RASAL1) functions as a tumor suppressor in vitro and may play an important role in the development of gastric cancer. However, whether or not RASAL1 suppresses tumor growth in vivo remains to be determined. In the present study, we investigated the role of RASAL1 in gastric carcinogenesis using an in vivo xenograft model. A lentiviral RASAL1 expression vector was constructed and utilized to transfect the human poorly differentiated gastric adenocarcinoma cell line, BGC-823. RASAL1 expression levels were verified by quantitative real-time RT-PCR and Western blotting analysis. Then, we established the nude mice xenograft model using BGC-823 cells either over-expressing RASAL1 or normal. After three weeks, the results showed that the over-expression of RASAL1 led to a significant reduction in both tumor volume and weight compared with the other two control groups. Furthermore, in xenograft tissues the increased expression of RASAL1 in BGC-823 cells caused decreased expression of p-ERK1/2, a downstream moleculein the RAS/RAF/MEK/ERK signal pathway. These findings demonstrated that the over-expression of RASAL1 could inhibit the growth of gastric cancer by inactivation of the RAS/RAF/MEK/ERK pathway in vivo. This study indicates that RASAL1 may attenuate gastric carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25735335     DOI: 10.7314/apjcp.2015.16.3.1077

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  Targeting CD133(+) laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles.

Authors:  Xinmeng Qi; Dan Yu; Bo Jia; Chunshun Jin; Xueshibojie Liu; Xue Zhao; Guangxin Zhang
Journal:  Tumour Biol       Date:  2015-09-09

2.  Downregulation of RASAL2 promotes the proliferation, epithelial-mesenchymal transition and metastasis of colorectal cancer cells.

Authors:  Zeming Jia; Weidong Liu; Liansheng Gong; Zhongfu Xiao
Journal:  Oncol Lett       Date:  2017-01-10       Impact factor: 2.967

3.  ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.

Authors:  Lijun Ma; Ting Liu; Yiran Jin; Jun Wei; Yinxue Yang; Hongquan Zhang
Journal:  Tumour Biol       Date:  2016-07-23

4.  GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers.

Authors:  Wei-Wei Xu; Da-Yu Liu; Ying-Chun Cao; Xiang-Yun Wang
Journal:  Int J Nanomedicine       Date:  2017-09-05

5.  miR-130b-5p promotes proliferation, migration and invasion of gastric cancer cells via targeting RASAL1.

Authors:  Hong Chen; Yiqiong Yang; Jing Wang; Duo Shen; Jiyi Zhao; Qian Yu
Journal:  Oncol Lett       Date:  2018-03-05       Impact factor: 2.967

6.  K-ras-ERK1/2 down-regulates H2A.XY142ph through WSTF to promote the progress of gastric cancer.

Authors:  Chao Dong; Jing Sun; Sha Ma; Guoying Zhang
Journal:  BMC Cancer       Date:  2019-05-31       Impact factor: 4.638

7.  RASAL1 induces to downregulate the SCD1, leading to suppression of cell proliferation in colon cancer via LXRα/SREBP1c pathway.

Authors:  Guangchuan Wang; Zhen Li; Xiao Li; Chunqing Zhang; Lipan Peng
Journal:  Biol Res       Date:  2019-12-17       Impact factor: 5.612

8.  Overexpression of RASAL1 Indicates Poor Prognosis and Promotes Invasion of Ovarian Cancer.

Authors:  Rui-Xia Chang; Ai-Ling Cui; Lu Dong; Su-Ping Guan; Ling-Yan Jiang; Cong-Xiu Miao
Journal:  Open Life Sci       Date:  2019-05-21       Impact factor: 0.938

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.